Breast Cancer | Specialty

Preclinical Observations on Eribulin for Breast Cancer

April 19th 2017

Dual MOA for Eribulin in Breast Cancer

April 19th 2017

Role of MOA When Choosing Breast Cancer Chemotherapy

April 19th 2017

Evolution of Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Optimizing Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Chemotherapy Use for Breast Cancer Subtypes

April 19th 2017

Chemotherapy for Metastatic Breast Cancer in 2017

April 19th 2017

Tripathy Offers Insights on Future of Breast Cancer From SABCS, ASCO

April 19th 2017

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer

April 18th 2017

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.

Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer

April 18th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

Clinicians Must Evaluate Evidence Needed in Real-World Practice

April 17th 2017

Research on a scalp-cooling device to help patients with breast cancer avoid hair loss during chemotherapy illustrates this question: what level of evidence might individual clinicians require before they would suggest, recommend, or support the use of a particular approach in treating patients outside the realm of the mandates of governmental agencies or payers?

Expert Discusses Recommending Against Prophylactic Mastectomy

April 14th 2017

Steven J. Katz, MD, discusses his study of patient reaction to surgeon recommendations about contralateral prophylactic mastectomy for patients with breast cancer.

Dr. Disis on Immunotherapy in Breast Cancer

April 14th 2017

Mary L. (Nora) Disis, MD, professor of Medicine, Department of Medicine, University of Washington School of Medicine, discusses immunotherapy for patients with breast cancer.

Dr. Cardoso on the Rationale Behind the Global mBC Vision 2025 Call-to-Action

April 13th 2017

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Campalimaud Clinical Cancer Center, discusses the rationale behind the Global mBC Vision 2025 Call-to-Action.

HER2-Enriched Subtype Predicts Response to Dual HER2 Blockade in Early Breast Cancer

April 10th 2017

According to results from the PAMELA trial, women with the HER2-enriched subtype of early-stage, HER2-positive breast cancer were more likely to have a pathological complete response when treated with dual HER2-blockade.

Tailoring Therapy for HR-Positive Breast Cancer

April 8th 2017

Experts discuss the most effective ways to use new targeted therapies for patients with advanced hormone receptor-positive breast cancer in an OncLive Peer Exchange® panel.

Novel HER2 Inhibitor May Help Treat Brain Tumors in Breast Cancer Patients

April 7th 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

April 7th 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

April 5th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.